All Online Health Education Programs
(For Health Professionals)
Interactive Medical Intelligence Zone for Stroke Prevention in Atrial Fibrillation
The most comprehensive multimedia CME resource for SPAF. The “Best and the Brightest” address the trickiest and toughest questions, issues and clinical dilemmas in stroke prevention in Atrial Fibrillation.
Health Education Online Programs:
Cardiovascular Risk Reduction in the Setting of Type 2 Diabetes and ACS:
Webcast
Gilles Montalescot, MD, PhD, and Richard W. Nesto, MD, co-chair an international symposium that focuses on reducing cardiovascular risk among diabetic patients in the setting of ACS. The program co-chairs, joined by experts from Europe and the United States, focus on glucose regulation, insulin resistance, and lipid modification strategies for reducing cardiovascular risk.
Webcast
Thrombosis-related complications are common in patients with malignant diseases. What do the latest clinical trials teach us about optimizing prevention, risk assessment, and managing thrombotic complications in the setting of cancer? Dr. Samuel Z. Goldhaber of Harvard Medical School is joined by Craig Kessler, MD, Georgetown University Medical Center; Alok A. Khorana, MD, FACP, University of Rochester; and Frederick R. Rickles, MD, The George Washington University School of Medicine and Sciences, in a comprehensive review of the latest developments and research in cancer and thrombosis.
Webcast
Program Chair Samuel Z. Goldhaber of Harvard Medical School is joined by a distinguished panel of experts in a review of late-breaking trials for new and established therapies for stroke prevention in atrial fibrillation (SPAF). Dr. Goldhaber uses risk stratification to navigate the complex maze of SPAF.
Webcast
Gerald V. Naccarelli, M.D., the Bernard Trabin Chair in Cardiology, Professor of Medicine, and Chief, Division of Cardiology at Penn State Heart and Vascular Institute, reviews principles, evidence, and guidelines focusing on rhythm control and optimizing outcome domains in patients with atrial fibrillation.
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads a panel of international experts in the iQ&A Interactive Medical Intelligence Zone for Stroke Prevention in Atrial Fibrillation. Dr. Goldhaber and this forum of experts address the most pressing questions on the rapidly evolving, multidimensional landscape of risk-specific interventions for stroke prevention in the setting of atrial fibrillation.
Charles Faiman, MD, of the Cleveland Clinic, chairs an expert faculty as they study the latest developments and advances in oral therapy for Type 2 diabetes, with a focus on DPP-4 inhibition and the available options, strategies and combinations for incretin-based therapy (IBT).
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads a panel of thrombosis experts in the iQ&A Interavtive Medical Intelligence Zone for VTE Prophylaxis. Dr. Goldhaber and this forum of experts address the most pressing questions on the challenges and benefits of completion of prophylaxis and self-administration of low molecular weight heparin in the post-hospitaliization setting.
This multiple track educational program is co-sponsored by the North American Thrombosis Forum (NATF), Twine Clinical, and The Indiana University School of Medicine. The curricula are designed to demonstrate participant performance improvement and includes: 1) An Overview of Prevention of VTE as a national healthcare priority; 2) Post-Partum VTE, 3) VTE and Cancer; and 4) Heparin-Induced Thrombocytopenia.
Peter Libby, MD, FACC, Chief of Cardiovascular Medicine at Brigham and Women’s Hospital, chairs an expert faculty as they study the latest developments and landscape changes in atrial fibrillation, focusing on emerging strategies for stroke prevention.
Atrial Fibrillation: Emerging Perspectives in Stroke Prevention for the Cardiovascular Specialist (NEW!).
Deepak Bhatt, MD, of Harvard Medical School and the VA Boston Healthcare System, examines the evidence, guidelines, and recent studies on oral antiplatelet therapy in the front lines of cardiovascular practice, with a special emphasis on the myths and truths of drug interactions with PPIs.
Antiplatelet WRAP: Focus on Oral Antiplatlet Therapy and PPI-Drug Interactions in ACS (NEW!)
VTE is considered the most prevalent preventable cause of death during hospitalization, with approximately one out of ten hospital deaths being ascribed to PE. Yet, appropriate preventive measures continue to be under-prescribed, especially in the CV setting, even though safe and effective prophylactic measures are now widely available for patients with a broad range of CV conditions including CAD, heart failure, ACS, and related condition. Samuel Z. Goldhaber, MD, chairs an international congress symposium on new frontiers in the science and medicine of VTE, with a focus on the CV environment.
Venous Thromboembolism: Focus on Heart Failure, Coronary Artery Disease and Pulmonary Hypertension (NEW!)
VTE is considered the most prevalent preventable cause of death during hospitalization, with approximately one out of ten hospital deaths being ascribed to PE. Yet, appropriate preventive measures continue to be under-prescribed, especially in the CV setting, even though safe and effective prophylactic measures are now widely available for patients with a broad range of CV conditions including CAD, heart failure, ACS, and related condition. Samuel Z. Goldhaber, MD, chairs an international congress symposium on new frontiers in the science and medicine of VTE, with a focus on the CV environment.
Extended Anticoagulation Prophylaxis of Patients Post-Hospitalization (NEW!)
Thursday, April 1, 2010 at 12:00PM, EST
Register Now!
Dr. Brian Musiak, Director of Pharmacy at The Westerly Hospital in Rhode Island will be presenting the Extended Anticoagulation Prophylaxis of Patients Post-Hosptialization.
Anticogulation Monitoring-(CE credit for Pharmacists!)
Thursday, February 25, 2010 at 12:00PM, EST
Register Now!
Dr. Michael Smith, Clinical Coordinator at Backus Hospital in Norwich, CT will present the Anticoagulation Monitoring Webinar. Dr. Smith will explain the role of INR, Factor Xa and partial prothrombin time in monitoring anticoagulation therapy, describe monitoring parameters for specific anticoagulation therapies, discuss the counseling points for patients on anticoagulation therapy and formulate case-specific monitoring of patients.
Cases in Drug Interactions with Anticoagulation Therapy
Philip Hritcko, Pharm.D, CACP, Director of Experiential Education at the University of Connecticut School of Pharmacy will discuss the pharmacokinetic and pharmacodynamic mechanisms for warfarin drug interactions. This webinar will include actual case studies in addition to the presentation of clinical data.
DVT Webinar for Patients
Ruth Morrison, R.N, B.S.N., C.V. N., Steering Committee Member will be leading a presentation about DVT. See the attached webinar invitation for more information.
Thrombosis Management
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an international panel of cardiologists and thrombosis experts in The iQ&A Interactive Medical Intelligence Zone for Thrombosis Management. Dr. Goldhaber and this world forum of experts address the most pressing questions on advances in anticoagulation-based therapy in the setting of atrial fibrillation, VTE and heart disease.
DVT & PE
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an international panel of cardiologists and thrombosis experts in The iQ&A Interactive Medical Intelligence Zone for DVT and PE. Dr. Goldhaber and this world forum of experts answer the most fequently asked questions about the role of low molecular weight heparins in the prevention of DVT and PE across the arteriovenous ris spectrum.
The New Frontiers in Atrial Fibrillation
There has been growing interest in identifying oral anticoagulants that can achieve safe and effective prophylaxis for stroke prevention, with minimal risk of bleeding and without the need for monitoring of clotting parameters. Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an expert faculty in discussing the latest strategies for stroke prevention in the setting of atrial fibrillation, reviews the latest American College of Chest Physicians and ACC/AHA Guidelines for stroke prevention, and analyzes recent landmark clinical trials in anticoagulation.
Clots, Contrast Media and Catheterization
Strategies for reducing mortality and preventing adverse thrombotic and renal events in patients undergoing coronary angioplasty have recently focused not only on traditional antithrombotic strategies with antiplatelets and anticoagulants, but on selection of contrast media. Steven V. Manoukian, MD, FACC, leads an expert interventionalist panel in discussing strategies for improving outcomes in the setting of PCI through contrast media selection.
Antiplatelet Therapy in the Catheterization Laboratory
An international expert faculty, chaired by Deepak L. Bhatt, MD of Harvard Medical School and Shamir Mehta, MD, of McMaster University, discuss the science and mechanisms of antiplatelet therapy, offering a unique, informed, and balanced perspective on rapidly evolving dimensions and controversies about antiplatelet management in the cardiac catheterization laboratory. Drawing on late-breaking trials, this program presents new and critically important data from the latest investigations—trials which, already, are having a decisive impact on the way interventional cardiologists should analyze, risk stratify, and manage patients requiring oral agents for invasive management of acute, ischemic heart disease.
The Q & A for Cancer and Thrombosis
Program Chairman Samuel Z. Goldhaber, MD, of Harvard Medical School, leads an international panel of thrombosis experts in The World Forum iQ&A Medical Intelligence Zone for Cancer and Thrombosis. Oncologists, hematologists, cardiologists and other thrombosis experts answer the most pressing questions about the prevention and management of thrombosis in the setting of cancer.
CardioContrastWRAP: The Role Of Ionic, Low Osmolar Contrast Media (LOCM) for Thrombosis Reduction in the Setting of PCI
In this edition of CardioContrastWRAP, Steven V. Manoukian, MD, FACC, FSCAI, Director of Cardiovascular Research at the Sarah Cannon Research Institute, examines the role of ionic, low osmolar contrast media (LOCM ) for thrombosis reduction in the setting of percutaneous coronary intervention. Dr. Manoukian reviews landmark trials comparing contrast media, with an emphasis on the effects of MACE in the setting of PCI.
VTECancerWRAP- A Leading Investigator, First Person Clinical Report: Focus on the Foundation Role of LMWH for VTE Management in Patients with Cancer
Thrombosis-related complications are common in patients with malignant diseases. Estimates of the prevalence of cancer among patients with venous thrombosis vary from 3% to 18%, and up to 35% of patients with cancer eventually acquire a VTE at some point in the natural history of their disease. It is now understood that the pathogenic mechanisms of thrombosis in the cancer patient involve a complex interaction among the tumor cell, the patient, and the coagulation system. Risk factors and mechanisms for thrombosis include activation of the coagulation system, platelet activation, endothelial damage, indwelling venous access devices, direct effects of chemotherapy/hormonal therapy, and host inflammatory responses. With these issues in mind, this VTECancerWRAP: A Leading Investigator, First Person Clinical Report®is one-stop CME-accredited program that provides superior quality consultation, guidance, recommendations, and clinical directives for managing cancer patients with VTE. This multimedia program, accompanied by landmark trials, guideline statements, and PowerPoint® resources, is presented by Craig M. Kessler, MD, MACP, Professor of Medicine and Pathology, Director of Division of Coagulation in the Department of Laboratory Medicine, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
The Science and Medicine of VTE Prophylaxis: 3-Part ProgramDVT Risk Assessment and Intervention Upon Hospital Admission – Electronic ALERTs and LMWH-Based Therapy
The recent U.S. Surgeon General’s Report on Prevention of PE and DVT is a defining moment in the history of this disease state; and, represents a paradigm-changing call-to-action for hospital-based physicians. In this regard, new evidence demonstrating the value of electronic alerts for increasing the frequency of DVT prophylaxis, as well as new recommendations issued in the 8th ACCP Guidelines for prophylaxis of venous thromboembolism, have important implications and provide prudent, evidence-based strategies of clinicians managing patients at risk for DVT and PE. This landmark program, part I of three part DVT-WRAP series focused on The Science and Medicine of VTE Prophylaxis, is presented by the distinguished investigator and clinical scholar, Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, and Director of the Venous Thromboembolism Research Group at The Brigham and Women’s Hospital, Boston, Massachusetts. In this DVT-WRAP series, Dr. Goldhaber provides expert, evidence-based analysis of guidelines, landmark trials, and best practice management strategies that will optimize DVT risk assessment and initial management of patients upon admission to the hospital.
Dynamic DVT Risk Assessment During Hospital Admission – Focus on Prophylaxis Triggers and Optimal Use of LMWHs.
This landmark ThrombosisWRAP, part II of a three-part DVT-WRAP series, is focused on The Science and Medicine of VTE Prophylaxis, with a special emphasis on dynamic risk assessment of patients during hospitalization. This program is presented by the distinguished investigator and clinical scholar, Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, and Director of the Venous Thromboembolism Research Group at The Brigham and Women’s Hospital, Boston, Massachusetts.
LMWH-based Therapy in the Post-Hospitalization Phase – Discharge to Home and Skilled Nursing Facilities
This final program, part III of a three-part series on PE and DVT thromboprophylaxis, is focused on on discharge planning and prophylaxis strategies upon discharge from the hospital and in the chronic care setting. This program is presented by distinguished investigator and clinical scholar, Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, and Director of the Venous Thromboembolism Research Group at The Brigham and Women’s Hospital, Boston, Massachusetts.
Reducing Harm Associated with Anticoagulation Therapies
Patients with AF: Who Should be on Warfarin?
November 20, 2009, 12 noon – 1pm, EDT
Daniel Singer, MD, Chief, Clinical Epidemiology Unit, General Medicine Division, Massachusetts General Hospital and Lead Author, ACCP, Evidence-Based Clinical Practice Guidelines for Atrial Fibrillation, Chest 2008 will present Patients with AF: Who Should be on Warfarin? This audio conference call will include a review of the latest VTE guidelines, the evidence supporting their adoption, measures to assess their implementation, and review of the recent changes and the implications for hospital practice. Additionally, Dr. Singer will review systems to ensure inpatients are evaluated for potential VTE and prescribed the indicated prophylaxis, potential implementation challenges, and various approaches to increase effective implementation of VTE prophylaxis for all patients.
The Science and Medicine of Thrombosis in Cancer
Craig M. Kessler, MD, from Georgetown University Medical Center, chairs a faculty of thrombosis experts who discuss recent advances in thrombosis and cancer, with a focus on mechanisms, mortality, therapeutics, and optimal approaches to primary and secondary thromboprophylaxis in cancer patients. The presentations examine the evolving and foundation role of low molecular weight heparins, with an emphasis on applying guidelines and recent trials to the front lines of specialty practice.
Critical Advances in the Science and Medicine of Thromboembolic Disease
An international faculty of experts studies a range of panvascular thrombosis risk states, from secondary prevention of CAD and VTE prophylaxis, to stroke reduction in the setting of atrial fibrillation. The faculty presents evidence, trials, objectives, and controversies that inform our current and near future understanding of how to optimize residual risk reduction across the arterial and venous thrombosis risk continuum.
The Science and Medicine of Cancer and Thrombosis Management
This international CME Clinical Excellence WebCAST focused on The Science and Medicine of Thrombosis Management in the Setting of Cancer includes discussions of diagnosis, risk stratification, patient assessment, and outcome-effective prophylaxis and management of patients at risk for thrombosis-related disorders in the setting of cancer and related conditions. The educational and program objectives are to provide evidence-based information, using fair balance and scientific rigor, for clinical specialists, investigators, and academicians from the fields of oncology, thrombosis medicine, hematology, coagulation, and internal medicine to optimize care of patients at risk for thrombosis-related disorders. Join Program Chairman Craig Kessler, MD, of Georgetown University Medical Center, and distinguished presenters Samuel Z. Goldhaber, MD of Harvard Medical School and Frederick Rickles, MD, of The George Washington University, as they review the latest guidelines and strategies for managing the risk of thrombosis in the cancer patient.
Chronic Venous Insufficiency
This online Clinician Review discusses chronic venous insufficiency, including: disease mechanisms, diagnostic steps, differential diagnosis, treatment of venous ulcers, follow-up, and various additional concerns. Excerpt: “Varicose veins, venous stasis ulcers—the pain and disability of chronic venous disease are finally gaining appropriate attention among both clinicians and patients. A national screening program is raising awareness of venous insufficiency, and new management options are emerging to relieve patients’ symptoms and improve cosmetic appearance.”
Preventing Venous Thromboembolism in Orthopedic Surgery Patients: Evolving Guidelines and Standards of Care
This program will develop and present a comprehensive, national sequential medical education initiative to improve VTE prophylaxis and reduce the incidence of VTE among hospitalized patients at risk of VTE, with a specific focus on orthopedic surgery patients. The program will be designed to address systematic and individual barriers to appropriate prophylaxis. The program will discuss the current and evolving state of affairs of VTE prophylaxis in orthopedic surgery. Through the different deliverables, the program will discuss / highlight the literature and available guidelines regarding current prophylaxis agents, the external forces affecting VTE prophylaxis use in orthopedic surgery, the challenges to and potential strategies for improving VTE prophylaxis, and the literature and role of emerging anticoagulants under investigation.
International Cardiovascular Experts’ Roundtable: Focus on Mortality Reduction in STEMI
This innovative educational platform, The iQandA Interactive Medical Intelligence Zone for Interventional Cardiology, is a needs assessment-driven continuing medical education (CME) activity that utilizes international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine. Frequently AskedQuestions (FAQ) reflecting the clinical needs of practitioners are answered, analyzed, and discussed by our roundtable panel of international interventional cardiology experts, who provide evidence-based and clinically relevant guidance. This edition of the iQandA Interactive Medical Intelligence Zone—Focus on Mortality Reduction in STEMI, examines the recent ESC Guidelines for STEMI and their impact on practitioners.
The Pharmacogenetics of Warfarin Dosing
Variations in the VKORC1 and CYP2C9 genes alter warfarin metabolism. In August 2007, the FDA label for warfarin was updated to highlight genetic testing to predict warfarin response. David Herrington addresses the utility of genetic testing to more rapidly optimize warfarin dosing. The purpose of this program is to educate healthcare professionals on the use of pharmacogenetic data to predict response to oral anticoagulation therapy. This program is designed for healthcare professionals, particularly cardiologists, involved in the management of patients requiring chronic oral anticoagulation. At the conclusion of this program, participants will be able to: Outline the difficulties in optimizing warfarin dose; Review data linking genetic variations and warfarin sensitivity; Discuss the utility of genetic testing for warfarin sensitivity in the management of patients requiring oral anticoagulation. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Each participant should only claim credit commensurate with the extent of his/her participation in the activity.
DVT Prophylaxis in the Cancer Patient: A Year 2009 Update for The Health System Pharmacist
Participants in this CME-certified WebCAST will be able to: list the recent trials, research, and expert analysis of issues focused on thrombosis and cancer; outline specific strategies for risk-directed prophylaxis against DVT in at-risk patients with cancer; describe dose anticoagulation therapy for patients requiring prophylaxis in special patient populations; outline steps for avoiding medication errors using anticoagulation in cancer patients at risk for DVT; list the guidelines for DVT prophylaxis in cancer issued by the National Comprehensive Cancer Network (NCCN), the American College of Chest Physicians (ACCP), and the Surgeon General’s Report; assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT; risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis; apply the range of pharmacologic options available for thrombosis management in patients with mailignancy. This educational activity is designed for all physicians, pharmacists, academicians, researchers, investigators, and program directors from the fields of thrombosis, oncology, and haemostasis who manage patients with thrombosis-related disorders, including oncologists, hematologists, coagulation experts, internists, nurse practitioners, and related disciplines.
Cancer, Clotting, and Controversies: Critical Challenges and Landmark Advances in Thrombosis Management
Participants in this CME-certified WebCAST will: review recent trials, research, and expert analysis of issues focused on thrombosis and cancer; specify strategies for risk-directed prophylaxis against DVT in at risk patients with cancer; explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT; describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis; review landmark clinical trials focusing on DVT prophylaxis in patients with cancer; explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy. The program is intended for oncologists, hematologists, coagulation experts, internists, nurse practicioners, and related disciplines.
Prevention and Management of Venous Thromboembolism (VTE): Critical Challenges in Hospital Care – From Landmark Evidence to Optimal Clinical Practice
Participants in this CME-certified WebCAST will: learn how to apply current guidelines issued by national professional organizations and colleges, such as the ACCP, mandating risk-directed prophylaxis against DVT in at risk patients with medical and surgical conditions; learn to risk stratify medical and surgical patients, assess their likelihood for incurring DVT, and be aware of prophylaxis measures that can reduce the incidence of DVT in the patient populations; learn to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT; learn to risk stratify patients undergoing general and orthopedic surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis; learn how to apply landmark clinical trials focusing on DVT prevention in medical and surgical patients to their clinical practice; learn how to evaluate, select among, and appropriately use the range of pharmacologic options available for DVT prophylaxis, including warfarin, unfractionated heparin, and LMWHs. The educational activity is designed for physicians likely to encounter patients at risk for VTE, among them: primary care physicians, hospitalist physicians, critical care specialists/intensivists, orthopedic surgeons, general surgeons, hematologists, pulmonologists, thrombosis medicine anticoagulation specialists, hospital-focused internists, surgical oncologists, and emergency medicine specialists.
VTE Prophylaxis in the Setting of Cancer: A Year 2008 Best Practice Update on Cancer and Thrombosis
Participants in this CME-certified WebCAST will: review recent trials, research, and expert analysis of issues focused on thrombosis and cancer; learn how national guidelines for thrombosis prevention should impact management of patients with cancer; learn strategies for risk-directed prophylaxis against DVT in at risk patients with cancer; be able to explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT; be able to describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis; review landmark clinical trials focusing on DVT prophylaxis in patients with cancer; be able to explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy. The educational activity is designed for all physicians, academicians, researchers, investigators, and program directors from the fields of thrombosis, oncology, and haemostasis who manage patients with thrombosis-related disorders, including oncologists, hematologists, coagulation experts, internists, nurse practicioners, and related disciplines.
The Science and Medicine of Thrombosis Management: New Dimensions, Novel Approaches, and Landmark Practice Advances in Venous and Arterial Thrombosis Prevention and Treatment
Participants in this CME-certified WebCAST will: learn how to apply current guidelines issued by national professional organizations and colleges – including the AHA, ACC, AAN, and ACCP – mandating risk-directed prophylaxis against cerebral thromboembolic infarction in at risk patients with AF; learn how to apply current guidelines issued by national professional organizations and colleges, such as the ACCP, mandating risk-directed prophylaxis against DVT in at risk patients with medical and surgical conditions; learn about the coagulation cascade, mechanisms involved in inhibition at various points in the clotting cascade, and the rationale for developing and investigating agents with predictable anticoagulation, in the absence of clinical monitoring; learn to risk stratify medical and surgical patients, assess their likelihood for incurring DVT, and be aware of prophylaxis measures that can reduce the incidence of DVT in the patient populations. The symposium has been conceived for internal medicine, primary care, family medicine, neurology, thrombosis, preventive medicine, and geriatric specialists, as well as nurse practicioners, geriatric nurse practicioners, and consulting pharmacists.
Performance Improvement Strategies in Acute Coronary Syndromes
Treatment guidelines and hospital protocols exist for the management of patients with acute coronary syndromes (ACS), yet barriers that limit the optimal management of these patients are prevalent and achieving therapeutic goals remains a challenge. Join Christopher P. Cannon, MD, James W. Hoekstra, MD, and David M. Larson, MD, for a first-of-its-kind complimentary ACS performance improvement series, which will help you implement guideline-approved processes for your care of ACS patients, with a special focus on risk assessment, initial pharmacologic management, and door-to-needle/door-to-transfer times. Earn up to 20 AMA PRA Category 1 Credits? beginning today.
Cancer and Thrombosis Management: DVT Prophylaxis and Disease Modification in Cancer Patients
Participants in this CME-certified WebCAST will: review recent trials, research, and expert analysis of issues focused on thrombosis and cancer; learn how national guidelines for thrombosis prevention should impact management of patients with cancer; be able to explain how to assess and manage special needs of cancer patients at risk for DVT, with a focus on protecting against recurrent DVT; be able to describe how to risk stratify patients undergoing cancer surgery, and implement ACCP-mandated pharmacologic and non-pharmacologic measures aimed at DVT prophylaxis; review landmark clinical trials focusing on DVT prophylaxis in patients with cancer; be able to explain how to appropriately use the range of pharmacologic options available for thrombosis management in patients with malignancy. The educational activity is designed for all physicians, academicians, researchers, investigators, and program directors from the fields of thrombosis, oncology, and haemostasis who manage patients with thrombosis-related disorders, including oncologists, hematologists, coagulation experts, internists, nurse practicioners, and related disciplines.
Reducing Door-to-Treatment Times and Meeting New Performance Measures in Acute Coronary Syndromes
Podcast
In this Expert Commentary, Dr. Marc Cohen addresses various strategies for reducing the interval between arrival at the hospital and intracoronary balloon inflation during primary percutaneous coronary intervention, as well as reducing the interval between arrival at the hospital and administration of thrombolytic agents. Dr. Cohen also addresses barriers associated with these goals and discusses new performance measures in acute coronary syndromes.
Landmark Practice Advances in STEMI and ACS: New Advances in Mortality Reduction for STEMI and High Risk ACS — What do Recent Landmark Trials Teach Us?
Participants in this CME-certified WebCAST will learn how recently issued ESC and AHA/ACC guidelines for UA/Non ST-elevation myocardial infarction and STEMI are best applied to appropriately risk-stratified patients with UA/NSTEMI and STEMI. Participants will also learn to understand the implications of recent clinical data, trials, and recommendations on upstream management of STEMI and NSTEMI, and to apply guidelines and expert, consensus-based recommendations in order to optimize invasive vascular management of patients with high risk ACS.
Risk Stratification for Venous Thromboembolism
Webcast
While there is no universally accepted method for stratifying venous thromboembolism (VTE) risk for medical or surgical patients, Dr. Arthur Wheeler discusses various strategies in this Expert Commentary. Dr. Wheeler also discusses the barriers to VTE risk stratification and provides unique insight into the ways to overcome these barriers. Dr. Wheeler summarizes recent landmark deep vein thrombosis (DVT) prophylaxis clinical trials and the impact they may have on managing patients who must be correctly assessed for risk before the appropriate treatment can be given.
